Identification of CD141
CD141
Endothelial precursor cell (EPC)
Hepatocyte growth factor (HGF)
Hind limb ischemia
Multipotent stem cell (MSC)
Peripheral artery disease (PAD)
Thrombomodulin
Vascular precursor cell (VPC)
Vascularization
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
09
07
2024
accepted:
10
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Critical limb ischemia (CLI) is a condition characterized by insufficient blood flow to the lower limbs, resulting in severe ischemia and potentially leading to amputation. This study aims to identify novel vasculogenic precursor cells (VPCs) in human bone marrow and evaluate their efficacy in combination with bone marrow-derived mesenchymal stem cells (BM-MSCs) for the treatment of CLI. Ex vivo cultured VPCs and BM-MSCs from bone marrow were characterized and their effects on neovascularization and long-term tissue regeneration were tested in a mouse CLI model. VPCs, expressing high levels of hepatocyte growth factor and c-MET, were identified from human bone marrow aspirates. These cells exhibited strong vasculogenic capacity in vitro but possessed a cellular phenotype distinct from those of previously reported endothelial precursor cells in circulation or cord blood. They also expressed most surface markers of BM-MSCs and demonstrated multipotent differentiation ability. Screening of 376 surface markers revealed that VPCs uniquely display CD141 (thrombomodulin). CD141 Dual-cell therapy using BM-derived CD141
Sections du résumé
BACKGROUND
BACKGROUND
Critical limb ischemia (CLI) is a condition characterized by insufficient blood flow to the lower limbs, resulting in severe ischemia and potentially leading to amputation. This study aims to identify novel vasculogenic precursor cells (VPCs) in human bone marrow and evaluate their efficacy in combination with bone marrow-derived mesenchymal stem cells (BM-MSCs) for the treatment of CLI.
METHODS
METHODS
Ex vivo cultured VPCs and BM-MSCs from bone marrow were characterized and their effects on neovascularization and long-term tissue regeneration were tested in a mouse CLI model.
RESULTS
RESULTS
VPCs, expressing high levels of hepatocyte growth factor and c-MET, were identified from human bone marrow aspirates. These cells exhibited strong vasculogenic capacity in vitro but possessed a cellular phenotype distinct from those of previously reported endothelial precursor cells in circulation or cord blood. They also expressed most surface markers of BM-MSCs and demonstrated multipotent differentiation ability. Screening of 376 surface markers revealed that VPCs uniquely display CD141 (thrombomodulin). CD141
CONCLUSION
CONCLUSIONS
Dual-cell therapy using BM-derived CD141
Identifiants
pubmed: 39482744
doi: 10.1186/s13287-024-03994-9
pii: 10.1186/s13287-024-03994-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
388Subventions
Organisme : Ministry of Health and Welfare
ID : HI18C1492
Organisme : Ministry of Science and ICT, South Korea
ID : 23C0110L1
Informations de copyright
© 2024. The Author(s).
Références
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964–6.
pubmed: 9020076
doi: 10.1126/science.275.5302.964
Chambers SE, Pathak V, Pedrini E, Soret L, Gendron N, Guerin CL, Stitt AW, Smadja DM, Medina RJ. Current concepts on endothelial stem cells definition, location, and markers. Stem Cells Transl Med. 2021;10(S2):S54–61.
pubmed: 34724714
pmcid: 8560200
doi: 10.1002/sctm.21-0022
Yoder MC. Endothelial stem and progenitor cells (stem cells):(2017 Grover Conference Series). Pulm Circ. 2017;8(1):2045893217743950.
pubmed: 29099663
pmcid: 5731724
Medina RJ, O’Neill CL, Sweeney M, Guduric-Fuchs J, Gardiner TA, Simpson DA, Stitt AW. Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Med Genomics. 2010;3:1–13.
doi: 10.1186/1755-8794-3-18
Minami Y, Nakajima T, Ikutomi M, Morita T, Komuro I, Sata M, Sahara M. Angiogenic potential of early and late outgrowth endothelial progenitor cells is dependent on the time of emergence. Int J Cardiol. 2015;186:305–14.
pubmed: 25838182
doi: 10.1016/j.ijcard.2015.03.166
Fujisawa T, Tura-Ceide O, Hunter A, Mitchell A, Vesey A, Medine C, Gallogly S, Hadoke PW, Keith C, Sproul A. Endothelial progenitor cells do not originate from the bone marrow. Circulation. 2019;140(18):1524–6.
pubmed: 31657952
pmcid: 6818974
doi: 10.1161/CIRCULATIONAHA.119.042351
Yu QC, Song W, Wang D, Zeng YA. Identification of blood vascular endothelial stem cells by the expression of protein C receptor. Cell Res. 2016;26(10):1079–98.
pubmed: 27364685
pmcid: 5113308
doi: 10.1038/cr.2016.85
Wakabayashi T, Naito H, Suehiro J-i, Lin Y, Kawaji H, Iba T, Kouno T, Ishikawa-Kato S, Furuno M, Takara K. CD157 marks tissue-resident endothelial stem cells with homeostatic and regenerative properties. Cell Stem Cell. 2018;22(3):384–97.
pubmed: 29429943
doi: 10.1016/j.stem.2018.01.010
Zemaitis MR, Boll JM, Dreyer MA: Peripheral arterial disease. 2017.
Kawamoto A, Katayama M, Handa N, Kinoshita M, Takano H, Horii M, Sadamoto K, Yokoyama A, Yamanaka T, Onodera R. Intramuscular transplantation of G-CSF-mobilized CD34+ cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells. 2009;27(11):2857–64.
pubmed: 19711453
doi: 10.1002/stem.207
Idei N, Soga J, Hata T, Fujii Y, Fujimura N, Mikami S, Maruhashi T, Nishioka K, Hidaka T, Kihara Y. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Intervent. 2011;4(1):15–25.
doi: 10.1161/CIRCINTERVENTIONS.110.955724
Qadura M, Terenzi DC, Verma S, Al-Omran M, Hess DA. Concise review: cell therapy for critical limb ischemia: an integrated review of preclinical and clinical studies. Stem Cells. 2018;36(2):161–71.
pubmed: 29226477
doi: 10.1002/stem.2751
Raval Z, Losordo DW. Cell therapy of peripheral arterial disease: from experimental findings to clinical trials. Circ Res. 2013;112(9):1288–302.
pubmed: 23620237
doi: 10.1161/CIRCRESAHA.113.300565
Annex BH, Cooke JP. New directions in therapeutic angiogenesis and arteriogenesis in peripheral arterial disease. Circ Res. 2021;128(12):1944–57.
pubmed: 34110899
pmcid: 8538391
doi: 10.1161/CIRCRESAHA.121.318266
Huang NF, Stern B, Oropeza BP, Zaitseva TS, Paukshto MV, Zoldan J. Bioengineering cell therapy for treatment of peripheral artery disease. Arterioscler Thromb Vasc Biol. 2024;44(3):e66–81.
pubmed: 38174560
doi: 10.1161/ATVBAHA.123.318126
Dar A, Domev H, Ben-Yosef O, Tzukerman M, Zeevi-Levin N, Novak A, Germanguz I, Amit M, Itskovitz-Eldor J. Multipotent vasculogenic pericytes from human pluripotent stem cells promote recovery of murine ischemic limb. Circulation. 2012;125(1):87–99.
pubmed: 22095829
doi: 10.1161/CIRCULATIONAHA.111.048264
Park JJ, Kwon YW, Kim JW, Park GT, Yoon JW, Kim YS, Kim DS, Kwon SM, Bae SS, Ko K. Coadministration of endothelial and smooth muscle cells derived from human induced pluripotent stem cells as a therapy for critical limb ischemia. Stem Cells Transl Med. 2021;10(3):414–26.
pubmed: 33174379
doi: 10.1002/sctm.20-0132
MacAskill MG, Saif J, Condie A, Jansen MA, MacGillivray TJ, Tavares AA, Fleisinger L, Spencer HL, Besnier M, Martin E. Robust revascularization in models of limb ischemia using a clinically translatable human stem cell-derived endothelial cell product. Mol Ther. 2018;26(7):1669–84.
pubmed: 29703701
pmcid: 6035339
doi: 10.1016/j.ymthe.2018.03.017
Park SY, Lee H, Kwon YW, Park MR, Kim JH, Kim JB. Etv2-and fli1-induced vascular progenitor cells enhance functional recovery in ischemic vascular disease model—brief report. Arterioscler Thromb Vasc Biol. 2020;40(4):e105–13.
pubmed: 32075417
doi: 10.1161/ATVBAHA.119.313684
Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. 2005;7(4):452–64.
pubmed: 16212810
pmcid: 1871727
doi: 10.1215/S1152851705000232
Paschalaki KE, Randi AM. Recent advances in endothelial colony forming cells toward their use in clinical translation. Front Med. 2018;5:295.
doi: 10.3389/fmed.2018.00295
Attwood SW, Edel MJ. iPS-cell technology and the problem of genetic instability—Can it ever be safe for clinical use? J Clin Med. 2019;8(3):288.
pubmed: 30823421
pmcid: 6462964
doi: 10.3390/jcm8030288
Popescu S, Preda MB, Marinescu CI, Simionescu M, Burlacu A. Dual stem cell therapy improves the myocardial recovery post-infarction through reciprocal modulation of cell functions. Int J Mol Sci. 2021;22(11):5631.
pubmed: 34073327
pmcid: 8199446
doi: 10.3390/ijms22115631
Tamama K, Sen CK, Wells A. Differentiation of bone marrow mesenchymal stem cells into the smooth muscle lineage by blocking ERK/MAPK signaling pathway. Stem Cells Dev. 2008;17(5):897–908.
pubmed: 18564029
doi: 10.1089/scd.2007.0155
Kim S, Lee S, Lim J, Choi H, Kang H, Jeon NL, Son Y. Human bone marrow-derived mesenchymal stem cells play a role as a vascular pericyte in the reconstruction of human BBB on the angiogenesis microfluidic chip. Biomaterials. 2021;279: 121210.
pubmed: 34710793
doi: 10.1016/j.biomaterials.2021.121210
Loghmani H, Conway EM. Exploring traditional and nontraditional roles for thrombomodulin. Blood J Am Soc Hematol. 2018;132(2):148–58.
Kuo C-H, Huang Y-H, Chen P-K, Lee G-H, Tang M-J, Conway EM, Shi G-Y, Wu H-L. VEGF-induced endothelial podosomes via ROCK2-dependent thrombomodulin expression initiate sprouting angiogenesis. Arterioscler Thromb Vasc Biol. 2021;41(5):1657–71.
pubmed: 33730876
doi: 10.1161/ATVBAHA.121.315931
Xu Y, Zhou Y, Lin H, Hu H, Wang Y, Xu G. Toll-like receptor 2 in promoting angiogenesis after acute ischemic injury. Int J Mol Med. 2013;31(3):555–60.
pubmed: 23314218
doi: 10.3892/ijmm.2013.1240
Talele NP, Fradette J, Davies JE, Kapus A, Hinz B. Expression of α-smooth muscle actin determines the fate of mesenchymal stromal cells. Stem Cell Rep. 2015;4(6):1016–30.
doi: 10.1016/j.stemcr.2015.05.004
Tsuji-Tamura K, Morino-Koga S, Suzuki S, Ogawa M. The canonical smooth muscle cell marker TAGLN is present in endothelial cells and is involved in angiogenesis. J Cell Sci. 2021;134(15):jcs254920.
pubmed: 34338296
doi: 10.1242/jcs.254920
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7.
pubmed: 16923606
doi: 10.1080/14653240600855905
Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio P. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119(3):629–41.
pubmed: 1383237
doi: 10.1083/jcb.119.3.629
Müller B, Lang S, Dominietto M, Rudin M, Schulz G, Deyhle H, Germann M, Pfeiffer F, David C, Weitkamp T: High-resolution tomographic imaging of microvessels. In: Developments in X-ray tomography VI: 2008: SPIE; 2008: 89–98.
Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27.
pubmed: 27057123
doi: 10.4103/0976-0105.177703
Lee HC, An SG, Lee HW, Park J-S, Cha KS, Hong TJ, Park JH, Lee SY, Kim S-P, Kim YD. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia–a pilot study. Circ J. 2012;76(7):1750–60.
pubmed: 22498564
doi: 10.1253/circj.CJ-11-1135
Swaminathan A, Vemulapalli S, Patel MR, Jones WS: Lower extremity amputation in peripheral artery disease: improving patient outcomes. Vascular health and risk management 2014:417–424.
Bray LJ, Heazlewood CF, Atkinson K, Hutmacher DW, Harkin DG. Evaluation of methods for cultivating limbal mesenchymal stromal cells. Cytotherapy. 2012;14(8):936–47.
pubmed: 22587591
doi: 10.3109/14653249.2012.684379
Kim DY, Park G, Hong HS, Kim S, Son Y. Platelet-derived growth factor-bb priming enhances vasculogenic capacity of bone marrow-derived endothelial precursor like cells. Tissue Eng Regen Med. 2023;20(5):695–704.
pubmed: 37266845
pmcid: 10352207
doi: 10.1007/s13770-023-00546-9
Shi X, Zhang W, Yin L, Chilian WM, Krieger J, Zhang P. Vascular precursor cells in tissue injury repair. Transl Res. 2017;184:77–100.
pubmed: 28284670
pmcid: 5429880
doi: 10.1016/j.trsl.2017.02.002
Dight J, Zhao J, Styke C, Khosrotehrani K, Patel J: Resident vascular endothelial progenitor definition and function: the age of reckoning. Angiogenesis 2022:1–19.
Jang HH, Son Y, Park G, Park K-S. Bone marrow-derived vasculogenic mesenchymal stem cells enhance in vitro angiogenic sprouting of human umbilical vein endothelial cells. Int J Mol Sci. 2022;24(1):413.
pubmed: 36613857
pmcid: 9820660
doi: 10.3390/ijms24010413
Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif. 2020;53(1): e12712.
pubmed: 31730279
doi: 10.1111/cpr.12712
Qin Q, Qian J, Ge L, Shen L, Jia J, Jin J, Ge J. Effect and mechanism of thrombospondin-1 on the angiogenesis potential in human endothelial progenitor cells: an in vitro study. PLoS ONE. 2014;9(2): e88213.
pubmed: 24505433
pmcid: 3914943
doi: 10.1371/journal.pone.0088213
Smadja DM, d’Audigier C, Bieche I, Evrard S, Mauge L, Dias J-V, Labreuche J, Laurendeau I, Marsac B, Dizier B. Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. Arterioscler Thromb Vasc Biol. 2011;31(3):551–9.
pubmed: 21148423
doi: 10.1161/ATVBAHA.110.220624
Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008;28(9):1584–95.
pubmed: 18669889
pmcid: 5244813
doi: 10.1161/ATVBAHA.107.155960
Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation. 1999;100(13):1423–31.
pubmed: 10500044
doi: 10.1161/01.CIR.100.13.1423
Van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res. 2001;49(3):543–53.
pubmed: 11166267
doi: 10.1016/S0008-6363(00)00206-6